<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04227223</url>
  </required_header>
  <id_info>
    <org_study_id>R-I-002/307/2019</org_study_id>
    <nct_id>NCT04227223</nct_id>
  </id_info>
  <brief_title>Oxidative Balance in Opioid Therapy</brief_title>
  <official_title>Oxidative- Antioxidative Balance and Cognitive Functions During Opioid Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Bialystok</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Bialystok</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The oxidative - antioxidative balance is the crucial mechanism of opioid-induced
      immunomodulation. Additionally, impairement of cognitive function during opioid therapy is
      another important side- effect. This phenomenon was clearly described in opioids abuse. This
      is interesting to evaluate the importance of this subjects in chronic pain patients. The aim
      of the study was to investigate the oxidative - antioxidative homeostasis and cognitive
      functions using serum total oxidative capacity (TOC) and total antioxidative capacity (TAC)
      tests and Brain Derivered Neutrophic Factor (BDNF) in patient with chronic non-cancer pain
      treated with opioids.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The project was approved in Ethical Committee and supported by Medical University of
      Bialystok (Poland). The serum TOC and TAC measurements were performed in total group of 50
      adult patients: Study Group - 36 patients with chronic Low-Back Pain with opioids
      pharmacotherapy and Control Group - 14 patients, healthy volunteers. In Study Group
      anthropometric parameters, duration in opioid therapy, type of opioid, total dose, and form
      of application were registered.TOC, TAC, and BDNF measurements were performed using ImAnOx,
      PerOx, BDNF tests (Immundiagnostik, Germany).Data were analyzed using non-parametric tests.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 25, 2019</start_date>
  <completion_date type="Anticipated">February 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 25, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The serum measurements were performed in total group of 50 adult patients: Study Group - 36 patients with chronic Low-Back Pain with opioids pharmacotherapy and Control Group - 14 patients, healthy volunteers. I</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>oxidative balance</measure>
    <time_frame>6 months of opioids therapy</time_frame>
    <description>measurements of total oxidative capacity and total antioxidative capacity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>cognitive state</measure>
    <time_frame>6 months of opioids therapy</time_frame>
    <description>measurements of Brain-derived Neurotrophic Function</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Pain</condition>
  <condition>Opioids</condition>
  <arm_group>
    <arm_group_label>Study Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study Group - 36 patients with chronic Low-Back Pain with opioids pharmacotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control Group - 14 patients, healthy volunteers.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>biochemical measurements</intervention_name>
    <description>TOC,TAC, and BDNF measurements are performed using ImAnOx , PerOx and BDNF tests (Immundiagnostik, Germany)</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Study Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  minimally, 6 months opioid therapy in chronic Low- Back Pain

        Exclusion Criteria:

          -  depression, steroids- local or systemic administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Urszula Kosciuczuk</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University in Bialystok</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Urszula Kosciuczuk</name>
      <address>
        <city>Bialystok</city>
        <zip>15-276</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>December 29, 2019</study_first_submitted>
  <study_first_submitted_qc>January 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2020</study_first_posted>
  <last_update_submitted>February 12, 2020</last_update_submitted>
  <last_update_submitted_qc>February 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>neurological condition</keyword>
  <keyword>opioids</keyword>
  <keyword>oxidative balance</keyword>
  <keyword>pain</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

